The latest drugs for chronic lymphocytic leukemia (CLL) offer prolonged remission, along with a need for better tools to gauge their effectiveness: measurable residual disease (MRD) could be useful.
Subcutaneous (SC) administration of fluids and medications offers several benefits and advantages over the intravenous route, but the SC route is rarely used in the United States.
Response rates were superior to those seen with other single agents in patients with platinum-resistant disease and tumors positive for folate receptor alpha.